Φορτώνει......
Drug rechallenge and treatment beyond progression—implications for drug resistance
The established dogma in oncology for managing recurrent or refractory disease dictates that therapy is changed at disease progression, because the cancer is assumed to have become drug-resistant. Drug resistance, whether pre-existing or acquired, is largely thought to be a stable and heritable proc...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Nat Rev Clin Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2013
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4540602/ https://ncbi.nlm.nih.gov/pubmed/23999218 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2013.158 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|